NOVOLOG MIX 70/30 Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NOVOLOG MIX 70/30
Recent Clinical Trials for NOVOLOG MIX 70/30
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| The Cleveland Clinic | Phase 4 |
| Boston Medical Center | Phase 3 |
| Arecor Limited | Phase 1 |
Recent Litigation for NOVOLOG MIX 70/30
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| SANOFI-AVENTIS U.S. LLC v. MYLAN N.V. | 2017-10-24 |
| SANOFI-AVENTIS U.S. LLC v. MYLAN N v. | 2017-10-24 |
| Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc. | 2017-03-03 |
Pharmacology for NOVOLOG MIX 70/30
| Established Pharmacologic Class | Insulin Analog |
| Chemical Structure | Insulin |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLOG MIX 70/30 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021172 | See Plans and Pricing | 2013-08-20 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG MIX 70/30 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021172 | See Plans and Pricing | 2014-04-08 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG MIX 70/30 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021172 | See Plans and Pricing | 2014-12-02 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG MIX 70/30 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021172 | See Plans and Pricing | 2013-06-21 | Company disclosures |
| Novo Nordisk Inc. | NOVOLOG MIX 70/30 | insulin aspart protamine and insulin aspart | Injectable Suspension | 021172 | See Plans and Pricing | 2013-06-21 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NOVOLOG MIX 70/30 Derived from Patent Text Search
No patents found based on company disclosures
International Patents for NOVOLOG MIX 70/30
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | 9709845 | See Plans and Pricing |
| European Patent Office | 0549694 | See Plans and Pricing |
| Czech Republic | 20001034 | See Plans and Pricing |
| Hungary | 9904031 | See Plans and Pricing |
| Spain | 2073173 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NOVOLOG MIX 70/30
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C00214826/01 | Switzerland | See Plans and Pricing | FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| 132006901385693 | Italy | See Plans and Pricing | PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005 |
| 300021 | Netherlands | See Plans and Pricing | 300021, 20140621, EXPIRES: 20150622 |
| C300021 | Netherlands | See Plans and Pricing | PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623 |
| 41/2005 | Austria | See Plans and Pricing | PRODUCT NAME: NOVOMIX 70 - SUSPENSION, ENTHALTEND LOESLICHES INSULIN ASPART UND PROTAMINKRISTALLISIERTES INSULIN ASPART IM VERHAELTNIS 70:30; REGISTRATION NO/DATE: EU/1/00/142/017 - EU/1/00/142/022 20051005 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
